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UNCERTAINTIES PAGE
How big a problem is non-alcoholic fatty liver disease?
Quentin M Anstee senior lecturer and honorary consultant hepatologist 1 2, Stuart McPherson
consultant hepatologist 1 2, Christopher P Day professor of liver medicine 1 2
1Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; 2Regional Liver Unit, Freeman Hospital,
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
This is one of a series of occasional articles that highlight areas of
practice where management lacks convincing supporting evidence. The
series adviser is David Tovey, editor in chief, the Cochrane Library. To
suggest a topic for this series, please email us at
uncertainties@bmj.com.
Non-alcoholic fatty liver disease (NAFLD) represents a
spectrum of liver disease encompassing simple fatty infiltration
(steatosis), fat and inflammation (non-alcoholic steatohepatitis
(NASH)), and cirrhosis, in the absence of excessive alcohol
consumption (typically a threshold of <20 g a day for women
and <30 g a day for men is adopted). Simple steatosis has not
been associated with liver related morbidity, but NASH may
lead to progressive liver fibrosis, cirrhosis, and liver cancer, as
well as increase cardiovascular risk. NAFLD is strongly
associated with obesity, insulin resistance or type 2 diabetes
mellitus, and dyslipidaemia and may be considered the hepatic
manifestation of the metabolic syndrome.1 2 Estimates vary
between populations, but one large European study found
NAFLD in 94% of obese patients (body mass index (kg/m2)
>30), 67% of overweight patients (>25), and 25% of normal
weight patients.3 The overall prevalence of NAFLD in people
with type 2 diabetes ranges from 40% to 70%.3 With the advent
of increasingly sedentary lifestyles and changing dietary
patterns, the prevalence of obesity and insulin resistance have
increased and NAFLD has rapidly become the most common
cause of abnormal liver biochemistry in many developed
countries.4Despite substantial clinical and basic research in this
field, the true prevalence of NAFLD and NASH in the
community and the likely future disease burden remain unclear.
Furthermore, clinical uncertainties persist from diagnosis and
risk stratification through to treatment and long term follow-up.
Diagnosis and risk stratification—Much of the population is at
risk of NAFLD through being overweight or insulin resistant,
or both, but how best to identify patients with NAFLD remains
unclear, especially in patients with NASH, who are at greatest
risk of liver related complications. Many patients remain
undiagnosed and so it is not known what the true prevalences
of steatosis and steatohepatitis are and how many people will
actually develop liver related morbidity. These uncertainties
have made it difficult to establish strategies for service delivery
in routine clinical practice.
Prognosis—Althoughmost patients withNAFLDhave steatosis,
only aminority progress tomore advanced disease, characterised
by inflammation and subsequent fibrosis, cirrhosis, and
hepatocellular carcinoma. Studies indicate that about 5.4% of
patients with NASH develop complications of end stage liver
disease during long term follow-up.3-5 Such progression is
probably influenced by genetic and environmental factors, only
some of which have been identified.4 6 Recognised independent
risk factors for progression are age >45 years, presence of
diabetes (or severity of insulin resistance), obesity (body mass
index >30), and hypertension.4 The patients who do progress
often present late in the natural course of the disease and have
substantial liver related morbidity.
Treatment—Although current treatment is aimed at weight loss
and amelioration of the metabolic syndrome through lifestyle
interventions such as diet and exercise, insufficient evidence
exists to formulate authoritative and balanced clinical guidelines
for specific therapies.4
What is the evidence of the uncertainty?
The need for better evidence is apparent from the start of a
patient’s journey with NAFLD when we consider how best to
identify affected individuals in the population, how to stratify
individual risk of disease progression so that care may be
tailored to individual need, and how to establish strategies for
service delivery in routine clinical practice (box 1).We searched
PubMed, Medline, Embase, the Cochrane Library, the
metaRegister of Controlled Trials (mRCT), and clinicaltrials.gov
databases for relevant literature and information on clinical trials
(and other registered studies). No internationally accepted
evidence based consensus guidelines have been published on
this subject.
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Box 1 Main uncertainties in non-alcoholic fatty liver disease (NAFLD)
• The prevalence of NAFLD and non-alcoholic steatohepatitis (NASH) in an unselected general population
• The risk of liver related morbidity in a general community population of individuals with NAFLD or NASH
• The optimum method of identifying subjects with NASH in the community
• Clinically relevant, economic, and patient acceptable non-invasive techniques for differentiating steatosis from NASH
to identify those at greatest risk of liver related complications
• Strategies to facilitate sustainable modification of lifestyle to achieve weight loss and control the metabolic syndrome
• Effective drug treatments directed at the liver to control steatohepatitis and prevent fibrosis progression
How to diagnose NAFLD and NASH
NAFLD is often asymptomatic and commonly first discovered
as an incidental biochemical abnormality (often mildly raised
alanine aminotransferase levels) identified during routine blood
tests.7 The characteristic biochemical changes (a relatively
greater rise in alanine aminotransferase than in aspartate
aminotransferase) tend to reverse, and alanine aminotransferase
levels fall as hepatic fibrosis progresses. This means that
steatohepatitis with advanced disease may be present even in
those with relatively normal alanine aminotransferase levels.
Furthermore, hepatic fat content tends to diminish as cirrhosis
develops, and so NASH is probably underdiagnosed in the
setting of advanced liver disease, where it is thought to be the
underlying cause of 30-75% of cases where no specific cause
is readily identified (“cryptogenic cirrhosis”).4
Routine ultrasound imaging of the liver provides a qualitative
assessment of hepatic fat content; sensitivity is limited, however,
particularly when <33% of hepatocytes are steatotic.8 Several
methods (both proprietary and non-proprietary) have been
proposed for non-invasive quantification of hepatic fat and
inflammation, including magnetic resonance imaging or
spectroscopy and biomarker panels. However, evidence
supporting their use in wider clinical practice is still limited.4
Althoughmagnetic resonance techniques for lipid quantification
offer greater sensitivity for detecting milder degrees of steatosis,
they are often resource intensive and are not yet widely available
for routine clinical use.4 No widely accepted, reliable methods
are available yet for differentiating simple steatosis from
steatohepatitis in routine practice, other than liver biopsy.4
How to distinguish patients with progressive
disease
As hepatic fibrogenesis takes many years to progress, high
quality data from prospective trials on disease progression are
limited, particularly for the primary care setting. Currently, liver
biopsy is considered by many to be the optimum investigation
for assessing degree of inflammation and extent of liver fibrosis
as markers for risk of liver related morbidity. Accepting the
limitations, studies indicate that 25-33% of patients with NASH
have advanced fibrosis, including cirrhosis, at the time of
diagnosis, and that after adjustment for confounders NASH has
a similar fibrotic potential to that of chronic hepatitis C.3 4 Pooled
data suggest that about 38% of patients with NASHwill exhibit
progressive fibrosis and 21% will have some regression during
a mean 5.3 years’ follow-up.3A cohort study found that whereas
lone steatosis was not associated with increased risk of
morbidity, NASHwas associated with a >10-fold increased risk
of liver related death (2.8% v 0.2%) and a doubling of
cardiovascular risk (15% v 7.5%) over a mean follow-up of 13.7
years.5
Invasive tests are generally not appropriate or practical outside
specialist hepatology practice. There is a clear need to develop
non-invasive screening tests, ideally based on clinical history
and readily available anthropometric and biochemical indices,
to differentiate the patients at low risk of progression from those
with more aggressive disease. The identification of appropriate
biomarkers is an area of ongoing study, and the relative merits
of currently published clinical scores and elastography
techniques that identify patients with advanced fibrosis remain
controversial.7 9 10 These clinical scores and elastography
techniques indicate, however, only the current degree of fibrosis
and do not necessarily predict subsequent disease progression.
How best to advise and treat patients with
NAFLD and NASH
As recently highlighted in a position statement on NAFLD from
the European Association for the Study of the Liver, evidence
based clinical guidelines for this condition are badly needed but
insufficient evidence is currently available to formulate
authoritative and balanced guidance.4 No drugs are currently
licensed specifically for treating NASH, although evidence from
randomised control trials may support the use of specific insulin
sensitising agents in selected patient groups.4 The mainstay of
current treatment comprises lifestyle interventions to promote
weight loss, with trial evidence showing that weight reduction
of ≥7%maintained over 48 weeks is associated with significant
reduction in histological severity of NASH.11
Is ongoing research likely to provide
relevant evidence?
Box 2 summarises the main clinically relevant research themes.
From a public health perspective, the magnitude of disease
burden in the general population needs to be determined so that
consequent consumption of healthcare resources attributable to
NAFLD alone or as a cofactor in disease progression may be
predicted.
A search of ClinicalTrials.gov (www.clinicaltrials.gov) identifies
more than 250 ongoing studies examining diagnostic modalities,
physiology, and treatment of NAFLD. Several international
collaborative research programmes are under way. The FLIP:
Fatty Liver Inhibition of Progression consortium (www.flip-
fp7.eu/), sponsored by the European Union, has established
large prospective and retrospective patient cohorts to identify
genetic factors and pathophysiological mechanisms underlying
NASH and also to enable development of innovative diagnostic
methods for large scale screening and prognostic evaluation.
Similarly, the United States’ National Institute of Diabetes and
Digestive and Kidney Diseases has sponsored the Nonalcoholic
Steatohepatitis Clinical Research Network to coordinate clinical
research on aetiology, contributing factors, natural course, and
treatment (www.jhucct.com/nash/Default.asp).
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Box 2 Recommendations for further research
Population studies
• Development of appropriate methods for accurate determination of the prevalence of NAFLD and NASH in the
community
• Large community based studies to accurately determine the prevalence of NAFLD and NASH and the rate of disease
progression
Service development
• Studies to develop robust diagnostic strategies adapted for large scale screening
• Studies to develop strategies for effective triage of patients with NAFLD or NASH so that care can be tailored to the
individual’s risk of progression
• Biomarker discovery and clinical score development to help in discrimination of steatosis from NASH and/or predict
risk of fibrosis progression
Basic science and therapeutics development
• Research into genetic and environmental factors that influence risk and rate of disease progression as targets for
treatment
• Research into optimum lifestyle interventions to effect sustainable reduction in risk
• Studies of new therapeutic strategies to ameliorate NASH related liver damage and slow fibrosis
What should we do in the light of the
uncertainty?
Beyond prognostication, identification of patients with NAFLD
will change patient management by (a) providing a greater
impetus for modification of diet and lifestyle; (b) guiding drug
selection in patients with insulin resistance or diabetes (trial
evidence indicates that glitazone oral antidiabetic agents may
ameliorate steatohepatitis, although this has not translated into
reduced fibrosis4 12); and (c) allowing specific monitoring
strategies to be instituted if cirrhosis is present. As a marker of
the metabolic syndrome, identification of NAFLD should also
prompt aggressive modification of cardiovascular risk factors.
Until further evidence becomes available, management will be
dictated partly by the clinical situation. There is insufficient
evidence to support routine screening of the general population
outside epidemiological studies.4 As NASH is strongly
associated with insulin resistance, it may be appropriate to assess
patients with this condition for advanced liver disease, using
biochemical liver function tests and ultrasound imaging of the
liver.4No imagingmodality is ideal, and serum aminotransferase
levels are not highly sensitive for NAFLD. However, until better
methods are available, such pragmatic case identification is
probably warranted, on the basis of evidence that patients with
insulin resistance and increased aminotransferase levels are
much more likely to have advanced liver fibrosis.4 13
Where abnormalities are identified—either after targeted
investigation or as an incidental finding—investigations need
to exclude alternative causes (including viral, autoimmune, and
metabolic).7 14 Although liver biopsy currently remains the
optimum investigation for assessing degree of inflammation
and extent of liver fibrosis as markers for risk of liver related
morbidity, invasive tests are not generally appropriate or
practical outside specialist hepatology practice. A first line,
non-invasive assessment based on clinical history, readily
available anthropometric and biochemical indices, and
radiological investigation may be used to help exclude
alternative causes and differentiate the patients with mild disease
at low risk of progression from those with more aggressive
disease or advanced fibrosis that require additional assessment,
targeted intervention, and/or specialist referral.7 9 10 As an
example, the figure shows the algorithm that we use in our
region for investigating and assessing disease severity in patients
with NAFLD. Where this cannot be effectively implemented
or if clinical suspicion remains high, onward referral is advised.
The ultimate goal should be a multidisciplinary care pathway
that delivers case identification and risk stratification through
robust screening of those at greatest risk in the primary care
setting (and in cardiology and diabetology clinics), and staged
interventions first in the community and then through secondary
and tertiary care as clinical need dictates.
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Figure
Example algorithm for clinical assessment of patients at risk of non-alcoholic fatty liver disease (NAFLD), accepting the
many uncertainties that currently exist in this field. The NAFLD Fibrosis Score and FIB4 Score are examples of validated
non-proprietary clinical scores for estimating severity of liver fibrosis. Transient elastography (Fibroscan) uses ultrasound
to measure the propagation of an induced elastic shear wave through liver tissue, measuring degree of liver stiffness as a
surrogate for severity of hepatic fibrosis. The ELF (Enhanced Liver Fibrosis) test and Fibrotest are examples of proprietary
techniques that have also been proposed for the non-invasive assessment of liver fibrosis based on clinical biochemical
indices and/or panels of specific serum markers
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